AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26887585 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeting the Teachable Moment (TTMI)
Number of subjects: 173
Study 26887585 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard Lifestyle Management (SLM)
Number of subjects: 173
Study 26887585 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 173
Study 26887585 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 173
Study 24854326 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic professional oral health care (POHC)
Number of subjects: 26
Study 24854326 — intervention group
Group type: COMPARATOR
Intervention: Self-care
Number of subjects: 26
Study 21932426 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized peptide vaccine (PPV)
Number of subjects: 42
Study 21932426 — intervention group
Group type: COMPARATOR
Intervention: No PPV (historical control)
Number of subjects: 42
Study 19556637 — intervention group
Group type: EXPERIMENTAL
Intervention: Linex
Number of subjects: 100
Study 19556637 — intervention group
Group type: COMPARATOR
Intervention: Lacto-G
Number of subjects: 100
Study 18555932 — intervention group
Group type: EXPERIMENTAL
Intervention: S(‐)‐amlodipine nicotinate 2.5 mg QD
Number of subjects: 124
Study 18555932 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine besylate 5 mg QD
Number of subjects: 124
Study 16055451 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 270
Study 16055451 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal acupuncture
Number of subjects: 270
Study 16055451 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control
Number of subjects: 270
Study 16055451 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture vs Minimal acupuncture
Number of subjects: 270
Study 16055451 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture vs Waiting list
Number of subjects: 270
Study 12202014 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral treatment
Number of subjects: 128
Study 12202014 — intervention group
Group type: COMPARATOR
Intervention: 12-step treatment
Number of subjects: 128
Study 10781211 — intervention group
Group type: EXPERIMENTAL
Intervention: Graftskin plus compression therapy
Number of subjects: 120
Study 10781211 — intervention group
Group type: COMPARATOR
Intervention: Standard compression therapy (active control)
Number of subjects: 120
Study 7718369 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive suggestion
Number of subjects: 226
Study 7718369 — intervention group
Group type: COMPARATOR
Intervention: Control (no suggestions)
Number of subjects: 226
Study 1835704 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous transluminal angioplasty (PTA)
Number of subjects: 102
Study 1835704 — intervention group
Group type: COMPARATOR
Intervention: Vascular surgery
Number of subjects: 102
Study 6791596 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulised sodium cromoglycate (20 mg four times daily)
Number of subjects: 16
Study 6791596 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral choline theophyllinate (6.7 mg/kg four times daily)
Number of subjects: 16
Study 6791596 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 31576434 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic prevention and treatment of fever
Number of subjects: 184
Study 31576434 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 184
Study 28561231 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (overt) 200 mg
Number of subjects: 32
Study 26551771 — intervention group
Group type: COMPARATOR
Intervention: Salicylic acid 30% peeling
Number of subjects: 20
Study 26551771 — intervention group
Group type: EXPERIMENTAL
Intervention: Trichloroacetic acid 25% peeling
Number of subjects: 20
Study 23288758 — intervention group
Group type: EXPERIMENTAL
Intervention: Ligament balancing (LB) technique
Number of subjects: 77
Study 23288758 — intervention group
Group type: COMPARATOR
Intervention: Bone referencing (BR) technique
Number of subjects: 77
Study 21885077 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of albendazole (400mg)
Number of subjects: 611
Study 21885077 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of mebendazole (500mg)
Number of subjects: 611
Study 21885077 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of albendazole (400mg) and mebendazole (500mg)
Number of subjects: 611
Study 21885077 — intervention group
Group type: EXPERIMENTAL
Intervention: Double dose of albendazole (400mg/400mg)
Number of subjects: 611
Study 21885077 — intervention group
Group type: EXPERIMENTAL
Intervention: Double dose of mebendazole (500mg/500mg)
Number of subjects: 611
Study 21885077 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of double doses of albendazole and mebendazole
Number of subjects: 611
Study 21885077 — intervention group
Group type: COMPARATOR
Intervention: Single drugs (albendazole or mebendazole)
Number of subjects: 611
Study 21885077 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment (albendazole + mebendazole)
Number of subjects: 611
Study 19703830 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled salmeterol 50 microg + fluticasone propionate 500 microg twice daily
Number of subjects: 6112
Study 19703830 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6112
Study 19703830 — intervention group
Group type: EXPERIMENTAL
Intervention: Good adherence (>80% use of study medication)
Number of subjects: 6112
Study 19703830 — intervention group
Group type: COMPARATOR
Intervention: Poor adherence (<=80% use of study medication)
Number of subjects: 6112
Study 19703830 — intervention group
Group type: EXPERIMENTAL
Intervention: Good adherence
Number of subjects: 6112
Study 17854028 — intervention group
Group type: EXPERIMENTAL
Intervention: MYP (myeloid cell purging system) during treatment interruption
Number of subjects: 12
Study 17854028 — intervention group
Group type: COMPARATOR
Intervention: Control group (no MYP)
Number of subjects: 12
Study 14973305 — intervention group
Group type: EXPERIMENTAL
Intervention: Indinavir 800 mg q8h with rifabutin 300 mg qd
Number of subjects: 24
Study 14973305 — intervention group
Group type: EXPERIMENTAL
Intervention: Indinavir 800 mg q8h with rifabutin 150 mg qd
Number of subjects: 24
Study 14973305 — intervention group
Group type: COMPARATOR
Intervention: Indinavir alone
Number of subjects: 24
Study 14973305 — intervention group
Group type: COMPARATOR
Intervention: Rifabutin alone
Number of subjects: 24
Study 11169074 — intervention group
Group type: EXPERIMENTAL
Intervention: rBPI21
Number of subjects: 48
Study 11169074 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 9224337 — intervention group
Group type: EXPERIMENTAL
Intervention: Introducer tip catheter
Number of subjects: 4
Study 9224337 — intervention group
Group type: EXPERIMENTAL
Intervention: Introducer tip catheter in intermittent catheterization only group
Number of subjects: 4
Study 9224337 — intervention group
Group type: COMPARATOR
Intervention: Non-introducer tip catheter
Number of subjects: 4
Study 7946243 — intervention group
Group type: EXPERIMENTAL
Intervention: GH/hMG/hCG
Number of subjects: 26
Study 7946243 — intervention group
Group type: COMPARATOR
Intervention: hMG/hCG
Number of subjects: 26
Study 3348966 — intervention group
Group type: EXPERIMENTAL
Intervention: PUVA treatment for 14 days
Number of subjects: 7
Study 3348966 — intervention group
Group type: COMPARATOR
Intervention: UVA irradiation alone for 14 days
Number of subjects: 7
Study 31802233 — intervention group
Group type: EXPERIMENTAL
Intervention: Needle group (20 ml of 0.5% ropivacaine via needle)
Number of subjects: 34
Study 31802233 — intervention group
Group type: COMPARATOR
Intervention: Catheter group (20 ml of 0.5% ropivacaine via catheter)
Number of subjects: 34
Study 31802233 — intervention group
Group type: EXPERIMENTAL
Intervention: Needle group
Number of subjects: 34
Study 31802233 — intervention group
Group type: COMPARATOR
Intervention: Catheter group
Number of subjects: 34
Study 29610272 — intervention group
Group type: EXPERIMENTAL
Intervention: High-AGE meal (30,000 kU AGE)
Number of subjects: 10
Study 29610272 — intervention group
Group type: COMPARATOR
Intervention: Low-AGE meal (3,000 kU AGE)
Number of subjects: 10
Study 28236223 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcipotriol plus Betamethasone Dipropionate (Cal/BD) foam
Number of subjects: 159
Study 28236223 — intervention group
Group type: COMPARATOR
Intervention: Gel
Number of subjects: 159
Study 26148007 — intervention group
Group type: EXPERIMENTAL
Intervention: Ad35.CS.01 vaccine followed by two doses of RTS,S/AS01 (ARR-group)
Number of subjects: 55
Study 26148007 — intervention group
Group type: EXPERIMENTAL
Intervention: Three doses of RTS,S/AS01 (RRR-group)
Number of subjects: 55
Study 26148007 — intervention group
Group type: EXPERIMENTAL
Intervention: ARR-group
Number of subjects: 55
Study 26148007 — intervention group
Group type: EXPERIMENTAL
Intervention: Protected subjects (overall)
Number of subjects: 55
Study 24019080 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab (ADA) at 160/80/40 mg every two weeks
Number of subjects: 51
Study 24019080 — intervention group
Group type: COMPARATOR
Intervention: Azathioprine (AZA) at 2 mg/kg/day
Number of subjects: 51
Study 24019080 — intervention group
Group type: COMPARATOR
Intervention: Mesalamine at 3 g/day
Number of subjects: 51
Study 24019080 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab (ADA)
Number of subjects: 51
Study 24019080 — intervention group
Group type: COMPARATOR
Intervention: Azathioprine (AZA)
Number of subjects: 51
Study 24019080 — intervention group
Group type: COMPARATOR
Intervention: Mesalamine
Number of subjects: 51
Study 21349456 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel-eluting stent (PES)
Number of subjects: 80
Study 21349456 — intervention group
Group type: COMPARATOR
Intervention: Bare-metal stent (BMS)
Number of subjects: 80
Study 17495878 — intervention group
Group type: EXPERIMENTAL
Intervention: Goldenseal (Hydrastis canadensis)
Number of subjects: 16
Study 17495878 — intervention group
Group type: COMPARATOR
Intervention: Kava kava (Piper methysticum)
Number of subjects: 16
Study 16763853 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical vibration (100 Hz frequency and < 20 microm amplitude) applied to the quadriceps muscle, started one month after surgery, for short periods over three consecutive days.
Number of subjects: 0
Study 16763853 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated subjects standing on the operated leg).
Number of subjects: 0
Study 12586799 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent chemoradiotherapy (CCRT)
Number of subjects: 284
Study 12586799 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy (RT) alone
Number of subjects: 284
Study 10551572 — intervention group
Group type: COMPARATOR
Intervention: 8 mg bupivacaine
Number of subjects: 150
Study 10551572 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg ropivacaine
Number of subjects: 150
Study 10551572 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 mg ropivacaine
Number of subjects: 150
Study 10551572 — intervention group
Group type: EXPERIMENTAL
Intervention: 14 mg ropivacaine
Number of subjects: 150
Study 8678182 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced outreach counseling (N = 27)
Number of subjects: 94
Study 8678182 — intervention group
Group type: COMPARATOR
Intervention: Standard referral condition (N = 14)
Number of subjects: 94
Study 1830700 — intervention group
Group type: EXPERIMENTAL
Intervention: End-range extension movements
Number of subjects: 0
Study 1830700 — intervention group
Group type: EXPERIMENTAL
Intervention: End-range flexion movements
Number of subjects: 0
Study 1830700 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 6837621 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (0.3 mg daily)
Number of subjects: 24
Study 6837621 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin (15 mg daily)
Number of subjects: 24
Study 6837621 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of clonidine and prazosin
Number of subjects: 24
Study 30080456 — intervention group
Group type: EXPERIMENTAL
Intervention: Simplified default amount of financial information on Plan Finder
Number of subjects: 0
Study 30080456 — intervention group
Group type: COMPARATOR
Intervention: Standard Plan Finder tool with complex financial information
Number of subjects: 0
Study 27062079 — intervention group
Group type: EXPERIMENTAL
Intervention: Tapentadol prolonged release (PR) 100-250 mg bid
Number of subjects: 129
Study 27062079 — intervention group
Group type: COMPARATOR
Intervention: Overall tapentadol PR group
Number of subjects: 129
Study 25042089 — intervention group
Group type: EXPERIMENTAL
Intervention: Hi‐oleic peanuts
Number of subjects: 24
Study 25042089 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular peanuts
Number of subjects: 24
Study 25042089 — intervention group
Group type: COMPARATOR
Intervention: Potato crisps
Number of subjects: 24
Study 22552978 — intervention group
Group type: EXPERIMENTAL
Intervention: Phase III COG trial for de novo acute myeloid leukemia
Number of subjects: 416
Study 22552978 — intervention group
Group type: EXPERIMENTAL
Intervention: First chemotherapy course
Number of subjects: 416
Study 20683457 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation
Number of subjects: 136
Study 20683457 — intervention group
Group type: EXPERIMENTAL
Intervention: β-carotene supplementation
Number of subjects: 136
Study 18460997 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal strength training (half-squats, 4 sets of 4 repetitions, 3 times per week for 8 weeks)
Number of subjects: 17
Study 18460997 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal endurance training)
Number of subjects: 17
Study 15737446 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking with divided attention (dual-task)
Number of subjects: 20
Study 15737446 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking without divided attention (single-task)
Number of subjects: 20
Study 14595306 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic therapy
Number of subjects: 244
Study 10979948 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus and methotrexate (n = 90)
Number of subjects: 180
Study 10979948 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine and methotrexate (n = 90)
Number of subjects: 180
Study 10979948 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus and methotrexate
Number of subjects: 180
Study 10979948 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine and methotrexate
Number of subjects: 180
Study 8963141 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard Octopus strategy
Number of subjects: 23
Study 8963141 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic strategy of Weber
Number of subjects: 23
Study 1414967 — intervention group
Group type: EXPERIMENTAL
Intervention: MUFAs diet
Number of subjects: 38
Study 1414967 — intervention group
Group type: EXPERIMENTAL
Intervention: PUFAs diet
Number of subjects: 38
Study 3932271 — intervention group
Group type: EXPERIMENTAL
Intervention: L-thyroxine administration during radiation therapy
Number of subjects: 20
Study 3932271 — intervention group
Group type: COMPARATOR
Intervention: Control group (no L-thyroxine)
Number of subjects: 20
Study 30660342 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous NSAIDs
Number of subjects: 54
Study 30660342 — intervention group
Group type: COMPARATOR
Intervention: Trigger Point Injection (TPI)
Number of subjects: 54
Study 28845548 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical adhesive pads
Number of subjects: 39
Study 28845548 — intervention group
Group type: COMPARATOR
Intervention: Placebo (untreated zone)
Number of subjects: 39
Study 25353306 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate
Number of subjects: 96
Study 24518790 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive maximum urinary flow
Number of subjects: 945
Study 24518790 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive flow voiding time
Number of subjects: 945
Study 24518790 — intervention group
Group type: EXPERIMENTAL
Intervention: Detrusor pressure at maximum flow
Number of subjects: 945
Study 24518790 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypocontractility
Number of subjects: 945
Study 24518790 — intervention group
Group type: EXPERIMENTAL
Intervention: Bladder contractility index
Number of subjects: 945
Study 23508598 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteopathic manual treatment (OMT)
Number of subjects: 455
Study 23508598 — intervention group
Group type: COMPARATOR
Intervention: Sham OMT
Number of subjects: 455
Study 23508598 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound therapy (UST)
Number of subjects: 455
Study 23508598 — intervention group
Group type: COMPARATOR
Intervention: Sham UST
Number of subjects: 455
Study 19789442 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 366
Study 19789442 — intervention group
Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 366
Study 18088346 — intervention group
Group type: EXPERIMENTAL
Intervention: Formal EQA scheme (patients performing tests independently at home)
Number of subjects: 0
Study 18088346 — intervention group
Group type: COMPARATOR
Intervention: Supervised group (practices with supervision)
Number of subjects: 0
Study 18088346 — intervention group
Group type: COMPARATOR
Intervention: Venous sample compared with patients' POC device
Number of subjects: 0
Study 18088346 — intervention group
Group type: COMPARATOR
Intervention: Patients' POC compared with reference POC
Number of subjects: 0
Study 15678047 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical membrane (CV Seprafilm, Genzyme, Cambridge, Mass) applied in 350 patients
Number of subjects: 1024
Study 15678047 — intervention group
Group type: COMPARATOR
Intervention: Control group of 10 random reoperated patients
Number of subjects: 1024
Study 12543738 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (single dose)
Number of subjects: 57
Study 10778966 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymidylate synthase (TS) expression levels
Number of subjects: 243
Study 10778966 — intervention group
Group type: COMPARATOR
Intervention: Preoperative irradiation therapy (five doses of 5 Gy each)
Number of subjects: 243
Study 8863014 — intervention group
Group type: EXPERIMENTAL
Intervention: 320 ml of red wine (providing 30 g/day of alcohol)
Number of subjects: 11
Study 8863014 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 g/day of alcohol diluted in 320 ml of clear fruit juice
Number of subjects: 11
Study 8863014 — intervention group
Group type: EXPERIMENTAL
Intervention: 320 ml of dealcoholised red wine
Number of subjects: 11
Study 8863014 — intervention group
Group type: COMPARATOR
Intervention: Abstinence (4 weeks of complete withdrawal from any alcoholic beverage)
Number of subjects: 11
Study 1523877 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated hepatitis A vaccine (6.3 ng)
Number of subjects: 56
Study 1523877 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated hepatitis A vaccine (12.5 ng)
Number of subjects: 56
Study 1523877 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated hepatitis A vaccine (25 ng)
Number of subjects: 56
Study 1523877 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated hepatitis A vaccine (6.3-25 ng)
Number of subjects: 56
Study 1523877 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated hepatitis A vaccine (12.5 ng and 25 ng)
Number of subjects: 56
Study 1523877 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated hepatitis A vaccine
Number of subjects: 56
Study 1523877 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 2994989 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 24
Study 2994989 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 24
Study 2994989 — intervention group
Group type: COMPARATOR
Intervention: Captopril and Enalapril
Number of subjects: 24
Study 31771407 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher carbohydrates intake
Number of subjects: 84
Study 31771407 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein intake
Number of subjects: 84
Study 31771407 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary carbohydrate in GG genotype carriers
Number of subjects: 84
Study 31771407 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary protein in AA/AG carriers
Number of subjects: 84
Study 31771407 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary carbohydrate in AA/AG carriers
Number of subjects: 84
Study 28855226 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic (cephalexin if <6 months or co-trimoxazole if >6 months old) administered a day prior to VCUG and continued for 1 day post VCUG
Number of subjects: 120
Study 28855226 — intervention group
Group type: COMPARATOR
Intervention: No antibiotic (control group)
Number of subjects: 120
Study 26678954 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening starting at age 52 with 9 screens
Number of subjects: 3488
Study 26678954 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening starting at age 55 with 7 screens
Number of subjects: 3488
Study 26678954 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening starting at age 60 with 5 screens
Number of subjects: 3488
Study 26678954 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete attendees (3 to 9 invitations)
Number of subjects: 3488
Study 26678954 — intervention group
Group type: EXPERIMENTAL
Intervention: Age at termination of screening
Number of subjects: 3488
Study 25268910 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behaviorally oriented interventions
Number of subjects: 84
Study 22474933 — intervention group
Group type: EXPERIMENTAL
Intervention: Prime & Bond NT adhesive
Number of subjects: 76
Study 22474933 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearfil SE Bond adhesive
Number of subjects: 76
Study 22474933 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 76
Study 20438536 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-filtration plasmapheresis (DFPP)
Number of subjects: 40
Study 20438536 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunoadsorption (IA)
Number of subjects: 40
Study 20438536 — intervention group
Group type: COMPARATOR
Intervention: Intravenous immunoglobulin (IVIg)
Number of subjects: 40
Study 17689407 — intervention group
Group type: EXPERIMENTAL
Intervention: Circuit training (45 minutes, 3 times per week, for 8 weeks)
Number of subjects: 30